Moleculin Biotech, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Moleculin Biotech, Inc. (MBRX) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $48.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-18
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $48.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $88.00K.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $138.00K.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $99.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $48.00K 10-K · filed 2026-03-18 |
| 2024-12-31 | $88.00K 10-K · filed 2025-03-21 |
| 2023-12-31 | $138.00K 10-K · filed 2024-03-22 |
| 2022-12-31 | $99.00K 10-K · filed 2023-03-22 |
| 2021-12-31 | $12.00K 10-K · filed 2022-03-24 |
| 2021-03-31 | $26.00K 10-Q · filed 2021-05-12 |
| 2020-12-31 | $32.00K 10-K · filed 2021-03-24 |
| 2020-09-30 | $39.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $47.00K 10-Q · filed 2020-08-12 |
| 2020-03-31 | $55.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $64.00K 10-K · filed 2020-03-19 |
| 2019-09-30 | $74.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $47.00K 10-Q · filed 2019-08-16 |
| 2019-03-31 | $53.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |